1244 — 3D Medicines Share News
0.000.00%
Last trade - 00:00- HK$622.15m
- HK$233.49m
- CNY356.09m
Brief: 3D Medicines Sees Revenue For Six Months Between RMB343.8 Million To RMB361.4 Million
Brief: 3D Medicines Posts FY Loss Attributable Of RMB1.02 Bln
Brief: 3D Medicines Says 3D185 Granted Orphan-Drug Designation By U.S. FDA
Brief: 3D Medicines Biotechnology Shanghai Says Phase II Study Protocol Of Envafolimab Allowed To Proceed By U.S. FDA
China's 3D Medicines shines in Hong Kong debut, other newcomers fall